Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Max S Topp,Johannes Duell,Gerhard Zugmaier,Michel Attal,Philippe Moreau,Christian Langer,Jan Kroenke,Thierry Facon,Hermann Einsele,Gerd Munzert

doi:10.1182/blood-2018-99-109769

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Max S Topp, Johannes Duell + Show 8 more

Open Access

https://doi.org/10.1182/blood-2018-99-109769

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 43

Affiliation: University Hospital Würzburg, Amgen (Germany), Université de Toulouse, Kempten University of Applied Sciences, University of Ulm, Boehringer Ingelheim (Germany)

#Advisory Committees #Entity's Board + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Full Text